STAAR Surgical Company STAA
At closeNov 4, 2026, 7:24 AM EST
Pre-market · Nov 4, 7:24 AM ET
- YTD
- +9.01%
- 1 year
- -0.36%
- Market cap
- 1.26B
- Revenue (ttm)
- 339.59M
- Profit margin
- 1.13%
- EPS (ttm)
- 0.08
- Shares out
- 50.14M
- P/E ratio
- 314.63
- Forward P/E
- 22.65
- YTD return
- +9.01%
- 1-year return
- -0.36%
- Volume
- 691.15K
- Avg volume
- 867.32K
- Open
- 25.00
- Previous close
- 24.94
- Day's range
- 24.56 – 25.28
- 52-week range
- 15.59 – 35.87
- Beta
- 1.20
- Analysts
- Buy
- Price target
- 27.67 (+9.9%)
- Earnings date
- Nov 4, 2026
2Y -3.97 (-13.62%)
Key statistics
- Enterprise value
- 1.11B
- PEG ratio
- 0.76
- Price / sales
- 3.72
- Price / book
- 3.45
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 111.00%
- Free cash flow
- 15.35M
- Total cash
- 181.49M
- Total debt
- 35.94M
- Return on equity
- 1.09%
- Short % of float
- 15.37%
- 50-day average
- 22.45
- 200-day average
- 23.62
Analyst view
Consensus: buy
- Target (low)
- 19.00
- Target (mean)
- 27.67
- Target (high)
- 37.00
- Strong buy0
- Buy4
- Hold6
- Sell1
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 0.16857.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Oct 3, 2026 | 0.05075 | — | — | — |
| Aug 12, 2026 | Jul 3, 2026 | 0.2214 | 0.16 | -0.06 | -27.73% |
| May 13, 2026 | Apr 3, 2026 | 0.05422 | 0.38 | +0.33 | +600.85% |
| Mar 3, 2026 | Jan 2, 2026 | 0.18 | -0.20 | -0.38 | -211.11% |
| Nov 5, 2025 | Sep 26, 2025 | 0.18 | 0.46 | +0.28 | +155.56% |
| Aug 6, 2025 | Jun 27, 2025 | -0.56 | -0.3395 | +0.22 | +39.38% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 29, 2026 | Stifel | up | Hold | Buy |
| Sep 22, 2026 | Jefferies | main | Buy | Buy |
| Aug 17, 2026 | Stifel | main | Hold | Hold |
| Aug 13, 2026 | UBS | main | Sell | Sell |
| Aug 13, 2026 | Jefferies | main | Buy | Buy |
| Aug 13, 2026 | Wedbush | main | Outperform | Outperform |
About STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- staar.com
News
STAAR Surgical Appoints Pascal Aeschlimann as Vice President of Asia Pacific 
Earnings Preview: Staar Surgical (STAA) Q3 Earnings Expected to Decline 
STAAR Surgical Analyst Turns Bullish On Potential For ‘Meaningful’ Street Upside - This Staar Surgical Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
CarMax Posts Upbeat Q2 Earnings, Joins Iovance Biotherapeutics, Perella Weinberg Partners And Other Big Stocks Moving Higher On Tuesday 
Robinhood To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Tuesday 
Stifel Upgrades Staar Surgical to Buy, Raises Price Target to $31 
Stifel Maintains Hold on Staar Surgical, Lowers Price Target to $28 - UBS Maintains Sell on Staar Surgical, Lowers Price Target to $19
Wedbush Maintains Outperform on Staar Surgical, Lowers Price Target to $37
Your note
Sign in to keep a note on STAA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDREWS DEBORAH J | Chief Financial Officer | Conversion of Exercise of derivative security | Aug 13, 2026 | 38,910 |
| BROADWOOD PARTNERS, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Mar 12, 2026 | 0 |
| BUTCHER ARTHUR C | Director | Conversion of Exercise of derivative security | Jun 17, 2026 | 9,549 |
| FARRELL STEPHEN C | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 4, 2025 | 35,156 |
| FOUST WARREN | Chief Executive Officer | Conversion of Exercise of derivative security | Aug 13, 2026 | 95,816 |
| JIANG WEI | Director | Conversion of Exercise of derivative security | Jun 17, 2026 | 77,127 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Broadwood Capital, Inc. | 32.16% | 16,123,842 | 405.84M | Jun 29, 2026 |
| Blackrock Inc. | 13.42% | 6,731,154 | 169.42M | Jun 29, 2026 |
| Madison Avenue Partners, LP | 8.33% | 4,175,748 | 105.10M | Jun 29, 2026 |
| Yunqi Capital Ltd | 6.50% | 3,257,130 | 81.98M | Jun 29, 2026 |
| Point72 Asset Management, L.P. | 4.86% | 2,437,446 | 61.35M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 4.29% | 2,150,809 | 54.14M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 3.57% | 1,790,309 | 45.06M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.89% | 949,460 | 23.90M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.58% | 790,558 | 19.90M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.37% | 684,664 | 17.23M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.14% | 570,688 | 14.36M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 0.78% | 392,990 | 9.89M | Jun 29, 2026 |